5HT-Kinetics and Sensitivity of Human Blood Platelets: Variations with Age, Gender and Platelet Number

Summary

Platelet shape change and aggregation as well as serotonin (5–hydroxytryptamine; 5HT) content in platelets, spontaneous release of 5HT, 5HT plasma levels, urinary excretion of 5–hydroxyindoleacetic acid (5HIAA) and plasma (3–thromboglobulin (β–TG) were investigated in 45 healthy subjects (27 men, 18 women). Platelets from women were more susceptible to aggregation (both by 5HT and ADP) than platelets from men. However, in men, 5HT-induced shape change and aggregation as well as plasma β–TG concentration increased with age. In men, 5HT–induced platelet aggregation correlated positively with 5HT plasma levels. An inverse relationship was found in men between platelet number on the one hand and platelet 5HT content, 5HT release, 5HT plasma levels and urinary 5HIAA excretion rates on the other hand. In all subjects 5HT-induced platelet aggregation correlated negatively with platelet number

These results indicate that age and gender must be considered in designing clinical studies on 5HT and in evaluating human platelet 5HT kinetics. The platelet number seems to be related to 5HT kinetics of platelets and their reaction to 5HT in men. An age-dependent change in the reactivity of platelets to 5HT (rather than their absolute 5HT sensitivity) may contribute to the enhanced platelet turnover and higher incidence of cardiac events in older men

Keywords

5HT kinetics - 5HT sensitivity - Platelet function - Age - Sex

• References

• 1 Vanhoutte PM. Serotonin and the Cardiovascular System. Raven Press; New York: 1985. pp 123-135
• 2 Vanhoutte PM, Cohen RA. The elusory role of serotonin in vascular function and disease. Biochem Pharmacol 1983; 32: 3671-3674
• 3 Stahl SM, Woo DJ, Mefford IN, Berger PA, Ciaranello RD. Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. Am J Psychiatry 1983; 140: 26-30
• 4 Galzin AM, Langer SZ. Circadian rhythm of the B_max of [³H]-imipramine binding in rabbit platelets. Naunyn-Schmiedeberg’s Arch Pharmacol 1987; 336: 464-466
• 5 Buszewski B, Sebekova K, Bozek P, Stibranyi L, Jendrichovsky J, Novak I, Berek D. Evaluation of various bonded-phase materials for the off-line clean-up procedure of urinary 5–hydroxyindolacetic acid prior to its determination by HPLC. Chromatographia 1986; 22: 299-302
• 6 Laubscher A, Pletscher A. Shape change and uptake of 5–hydroxytryptamine in human blood platelets: action of neuropsychotropic drugs. Life Sci 1979; 24: 1833-1840
• 7 Born GV R, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
• 8 De Clerck F. A contribution to the role of 5–hydroxytryptamine in blood platelet function. University of Antwerp; Beerse: 1984. pp 23-29
• 9 Packham MA, Guccione MA, Nina M, Kinlough-Rathbone RL, Mustard JF. Effects of tris on responses of human and rabbit platelets to aggregating agents. Thromb Haemostas 1984; 51: 140-144
• 10 Honegger CG, Burri R, Langemann H, Kempf A. Determination of neurotransmitter systems in human cerebrospinal fluid and rat nervous tissue by high-performance liquid chromatography with online data evaluation. J Chromatogr 1984; 309: 53-61
• 11 Ludlam CA, Moore S, Bolton AE, Pepper DS, Cash JD. The release of a human platelet specific protein measured by a radioimmunoassay. Thromb Res 1975; 6: 543-548
• 12 Kaplan KL, Owen J. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981; 52: 199-202
• 13 Koch DD, Kissinger PI. Determination of tryptophan and several of its metabolites in physiological samples by reversed-phase liquid chromatography with electrochemical detection. J Chromatogr 1979; 164: 441-455
• 14 Yamanishi J, Sano H, Saito K, Furuta Y, Fukuzaki H. Plasma concentrations of platelet-specific proteins in different stages of essential hypertension: interactions between platelet aggregation, blood lipids and age. Thromb Haemostas 1985; 54: 539-543
• 15 Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975; 253: 355-357
• 16 Affolter H, Erne P, BÜrgisser E, Pletscher A. Ca²⁺ as messenger of 5HT₂ receptor stimulation in human blood platelets. Naunyn-Schmiedeberg’s Arch Pharmacol 1984; 325: 337-342
• 17 Karpatkin S. Heterogeneity of human platelets. VI. Correlation of platelet function with platelet volume. Blood 1978 51. 307-316
• 18 Wyatt RJ, Murphy DL, Belmaker R, Cohen S, Donelly CH, Pollin W. Reduced monoamine oxidase activity in platelets: A possible genetic marker for vulnerability to schizophrenia. Science 1973; 179: 916-918
• 19 Nies A, Robinson DL, Lamborn KR, Lampert RP. Genetic control of platelet and plasma monoamine oxidase activity. Arch Gen Psychiatry 1973; 28: 834-838
• 20 Friedhoff AJ, Miller JC, Karpatkin S. Heterogeneity of human platelets. VII. Platelet monoamine oxidase activity in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: its relationship to platelet protein density. Blood 1978 51. 317-323
• 21 De Mey CH, Vanhoutte PM. Effect of age and spontaneous hypertension on the tachyphylaxis to 5–hydroxytryptamine and angiotensin II in the isolated rat kidney. Hypertension 1981; 3: 718-724